Multi-institutional Retrospective Analysis of the Inhomogeneity Correction for Radiation Therapy of Lung Cancer
-
- MIZUNO Hideyuki
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences
-
- OKAMOTO Hiroyuki
- Radiation Oncology Divisions, National Cancer Center Hospital
-
- FUKUOKA Miyoko
- Department of Radiation Oncology, Tokyo Women's Medical University Hospital
-
- HANYU Yuji
- Department of Radiation Oncology, Tokyo Women's Medical University Hospital
-
- KUROOKA Masahiko
- Kanagawa Cancer Center
-
- KOHNO Ryosuke
- Particle Therapy Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
-
- NISHIO Teiji
- Particle Therapy Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
-
- KUMAZAKI Yu
- Department of Radiation Oncology, Saitama Medical University International Medical Center
-
- TACHIBANA Hidenobu
- Department of Radiation Oncology, The Cancer Institute Hospital of JFCR
-
- TAKAHASHI Yutaka
- Department of Radiation Oncology, Osaka University Graduate School of Medicine
-
- MORI Shinichiro
- Research Center for Charged Particle Therapy, National Institute of Radiological Sciences
-
- MASAI Norihisa
- Miyakojima IGRT Clinic
-
- SASAKI Koji
- Department of Radiological Technology, Gunma Prefectural Graduate School of Health Sciences
この論文をさがす
抄録
The purpose of this work is to retrospectively analyze the effect of the inhomogeneity correction using clinically treated plan of stage III non-small-cell lung cancer within multiple institutions in Japan. Twenty-five patients among five facilities of radiation therapy were registered for this study. The isocenter dose or D95 of PTV or other important values were compared with and without an inhomogeneity correction using model-based algorithm. The differences in isocenter dose were 4% average and 10% maximum for the first Anterior-Posterior opposed field plan to 40 Gy and 6% average and 11% maximum for the off-cord boost oblique field plan of 20 Gy. The differences in D95 dose were 1% average and 9% maximum for the first plan and 1% average and 6% maximum for the boost plan. D95 prescription seemed to be a superior method; however, its reliability depends on each clinical case. Additionally, maximum dose, minimum dose and mean dose for both the primary tumor and the metastatic lymph node were analyzed, and the minimum dose had the most impressive results. In some cases, the target volume had unintended underdose of more than 10%. Finally, an analysis of the organ at risk was added, and this showed no meaningful differences for the V20 of the lung and the maximum dose of the spinal cord. These results provide a standard for the effects of the inhomogeneity correction.
収録刊行物
-
- Journal of Radiation Research
-
Journal of Radiation Research 52 (1), 69-74, 2011
Journal of Radiation Research 編集委員会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680194293120
-
- NII論文ID
- 10027418331
-
- NII書誌ID
- AA00705792
-
- ISSN
- 13499157
- 04493060
-
- NDL書誌ID
- 10953759
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可